Waters Corporation announced on October 10, 2024, the introduction of a comprehensive suite of sample preparation enzymes, reagents, and waters_connect software. These new bioseparations tools are designed to simplify the sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LC-MS) analysis.
The combined workflow of these tools aims to accelerate and improve the development of innovative large molecule RNA-based pharmaceuticals, including new vaccines and emerging CRISPR RNA therapies. This addresses the critical need for more direct composition measurements to ensure the stability, safety, and effectiveness of these advanced treatments for patients.
The Waters RNA analytical tools, including RapiZyme RNAses and IonHance HFIP, are now available, with the new MAP Sequence App on waters_connect software scheduled for release on October 18, 2024. These tools are designed to enhance sequence coverage, LC-MS spectral data quality, and data interpretation, making them accessible even to LC-MS non-experts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.